Literature DB >> 2433294

Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix.

R Fridman, O Lider, Y Naparstek, Z Fuks, I Vlodavsky, I R Cohen.   

Abstract

The antigen-mediated induction of heparanase, an endoglycosidase capable of degrading heparan sulfate from the subendothelial extracellular matrix (ECM), was investigated in a rat T lymphocyte cell line reactive against the basic protein (BP) of myelin. We found that nonactivated T lymphocytes could be induced to express heparanase activity following exposure to soluble but not to ECM-bound BP. The induction of heparanase was immunologically specific and independent of the presence of syngeneic or allogeneic antigen presenting cells (APC). However, anti-IA antibodies inhibited heparanase expression. Soluble BP induced secretion of heparanase into the culture medium within minutes, despite inhibition of protein synthesis. Cell lysates of T lymphocytes contained heparanase activity. Thus, T lymphocytes secrete a preformed heparanase following exposure to specific antigen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433294     DOI: 10.1002/jcp.1041300113

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  25 in total

Review 1.  Membrane domains and the immunological synapse: keeping T cells resting and ready.

Authors:  Michael L Dustin
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix.

Authors:  R Hershkoviz; H Schor; A Ariel; I Hecht; I R Cohen; O Lider; L Cahalon
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 3.  Cell-matrix interactions during tumor invasion.

Authors:  J R Starkey
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

Review 4.  Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.

Authors:  Hayamitsu Adachi; Koichi Nakae; Shuichi Sakamoto; Chisato Nosaka; Sonoko Atsumi; Masabumi Shibuya; Nobuaki Higashi; Motowo Nakajima; Tatsuro Irimura; Yoshio Nishimura
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

Review 5.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

Review 6.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

7.  Extracellular matrix induces tumour necrosis factor-alpha secretion by an interaction between resting rat CD4+ T cells and macrophages.

Authors:  R Hershkoviz; D Gilat; S Miron; Y A Mekori; D Aderka; D Wallach; I Vlodavsky; I R Cohen; O Lider
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

8.  Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation.

Authors:  Olga Ostrovsky; Michael Korostishevsky; Itay Shafat; Margarita Mayorov; Neta Ilan; Israel Vlodavsky; Arnon Nagler
Journal:  J Leukoc Biol       Date:  2009-04-30       Impact factor: 4.962

9.  A disaccharide that inhibits tumor necrosis factor alpha is formed from the extracellular matrix by the enzyme heparanase.

Authors:  O Lider; L Cahalon; D Gilat; R Hershkoviz; D Siegel; R Margalit; O Shoseyov; I R Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 10.  Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues.

Authors:  Jeffrey L Platt; Lucile E Wrenshall; Geoffrey B Johnson; Marilia Cascalho
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.